bat 88

In SIMPLIFY-2, a randomized, open-label, multicenter, phase 3 study of patients with MF who had been previously treated with ruxolitinib, patients were randomized (2:1) to momelotinib 200 mg once a day or best available therapy (BAT; 88.5% receiving ruxolitinib at the investigator’s choice of dose, alone or in combination). rtp slot dewa 88